Report Detail

Pharma & Healthcare Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, Status and Forecast 2021-2027

  • RnM4315146
  • |
  • 07 May, 2021
  • |
  • Global
  • |
  • 118 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Global Chemotheraphy-induced Nausea and Vomitting Treatment Scope and Market Size
Chemotheraphy-induced Nausea and Vomitting Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotheraphy-induced Nausea and Vomitting Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Aloxi (Palonosetron)
Kytril (Granisetron)
Emend (Aprepitant)
Others

Segment by Application
Acute Nausea and Vomitting Treatment
Delayed Nausea and Vomitting Treatment
Anticipatory Nausea and Vomitting Treatment

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck & Co
Tesaro
Acacia Pharma
Aphios
Barr Laboratories
Baxter Healthcare
Eisai
Especificos Stendhal
F.Hoffmann La Roche
Mundipharma
Mylan Pharmaceuticals
OPKO Health
Orchid Healthcare


1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Aloxi (Palonosetron)
    • 1.2.3 Kytril (Granisetron)
    • 1.2.4 Emend (Aprepitant)
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Acute Nausea and Vomitting Treatment
    • 1.3.3 Delayed Nausea and Vomitting Treatment
    • 1.3.4 Anticipatory Nausea and Vomitting Treatment
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Perspective (2016-2027)
  • 2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Regions
    • 2.2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Share by Regions (2016-2021)
    • 2.2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Regions (2022-2027)
  • 2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Dynamic
    • 2.3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Trends
    • 2.3.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
    • 2.3.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
    • 2.3.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue
    • 3.1.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue (2016-2021)
    • 3.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Players (2016-2021)
  • 3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue
  • 3.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio
    • 3.4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2020
  • 3.5 Chemotheraphy-induced Nausea and Vomitting Treatment Key Players Head office and Area Served
  • 3.6 Key Players Chemotheraphy-induced Nausea and Vomitting Treatment Product Solution and Service
  • 3.7 Date of Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Type

  • 4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2016-2021)
  • 4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2022-2027)

5 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Application

  • 5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2016-2021)
  • 5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 6.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 6.2.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 6.2.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 6.2.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 6.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 6.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 6.3.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 6.3.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 6.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
    • 6.4.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
    • 6.4.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 7.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 7.2.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 7.2.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 7.2.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 7.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 7.3.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 7.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 7.3.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 7.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
    • 7.4.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
    • 7.4.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 8.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 8.2.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 8.3.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region
    • 8.4.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 9.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 9.2.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 9.2.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 9.2.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 9.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 9.3.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 9.3.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 9.3.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 9.4 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
    • 9.4.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
    • 9.4.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 10.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 10.2.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 10.3.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
    • 10.4.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 GlaxoSmithKline
    • 11.1.1 GlaxoSmithKline Company Details
    • 11.1.2 GlaxoSmithKline Business Overview
    • 11.1.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.1.4 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.1.5 GlaxoSmithKline Recent Development
  • 11.2 Helsinn
    • 11.2.1 Helsinn Company Details
    • 11.2.2 Helsinn Business Overview
    • 11.2.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.2.4 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.2.5 Helsinn Recent Development
  • 11.3 Heron Therapeutics
    • 11.3.1 Heron Therapeutics Company Details
    • 11.3.2 Heron Therapeutics Business Overview
    • 11.3.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.3.4 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.3.5 Heron Therapeutics Recent Development
  • 11.4 Merck & Co
    • 11.4.1 Merck & Co Company Details
    • 11.4.2 Merck & Co Business Overview
    • 11.4.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.4.4 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.4.5 Merck & Co Recent Development
  • 11.5 Tesaro
    • 11.5.1 Tesaro Company Details
    • 11.5.2 Tesaro Business Overview
    • 11.5.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.5.4 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.5.5 Tesaro Recent Development
  • 11.6 Acacia Pharma
    • 11.6.1 Acacia Pharma Company Details
    • 11.6.2 Acacia Pharma Business Overview
    • 11.6.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.6.4 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.6.5 Acacia Pharma Recent Development
  • 11.7 Aphios
    • 11.7.1 Aphios Company Details
    • 11.7.2 Aphios Business Overview
    • 11.7.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.7.4 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.7.5 Aphios Recent Development
  • 11.8 Barr Laboratories
    • 11.8.1 Barr Laboratories Company Details
    • 11.8.2 Barr Laboratories Business Overview
    • 11.8.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.8.4 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.8.5 Barr Laboratories Recent Development
  • 11.9 Baxter Healthcare
    • 11.9.1 Baxter Healthcare Company Details
    • 11.9.2 Baxter Healthcare Business Overview
    • 11.9.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.9.4 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.9.5 Baxter Healthcare Recent Development
  • 11.10 Eisai
    • 11.10.1 Eisai Company Details
    • 11.10.2 Eisai Business Overview
    • 11.10.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.10.4 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.10.5 Eisai Recent Development
  • 11.11 Especificos Stendhal
    • 11.11.1 Especificos Stendhal Company Details
    • 11.11.2 Especificos Stendhal Business Overview
    • 11.11.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.11.4 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.11.5 Especificos Stendhal Recent Development
  • 11.12 F.Hoffmann La Roche
    • 11.12.1 F.Hoffmann La Roche Company Details
    • 11.12.2 F.Hoffmann La Roche Business Overview
    • 11.12.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.12.4 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.12.5 F.Hoffmann La Roche Recent Development
  • 11.13 Mundipharma
    • 11.13.1 Mundipharma Company Details
    • 11.13.2 Mundipharma Business Overview
    • 11.13.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.13.4 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.13.5 Mundipharma Recent Development
  • 11.14 Mylan Pharmaceuticals
    • 11.14.1 Mylan Pharmaceuticals Company Details
    • 11.14.2 Mylan Pharmaceuticals Business Overview
    • 11.14.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.14.4 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.14.5 Mylan Pharmaceuticals Recent Development
  • 11.15 OPKO Health
    • 11.15.1 OPKO Health Company Details
    • 11.15.2 OPKO Health Business Overview
    • 11.15.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.15.4 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.15.5 OPKO Health Recent Development
  • 11.16 Orchid Healthcare
    • 11.16.1 Orchid Healthcare Company Details
    • 11.16.2 Orchid Healthcare Business Overview
    • 11.16.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.16.4 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.16.5 Orchid Healthcare Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Summary:
    Get latest Market Research Reports on Chemotheraphy-induced Nausea and Vomitting Treatment. Industry analysis & Market Report on Chemotheraphy-induced Nausea and Vomitting Treatment is a syndicated market report, published as Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, Status and Forecast 2021-2027. It is complete Research Study and Industry Analysis of Chemotheraphy-induced Nausea and Vomitting Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    3,088.80
    4,633.20
    6,177.60
    3,603.60
    5,405.40
    7,207.20
    590,031.00
    885,046.50
    1,180,062.00
    325,143.00
    487,714.50
    650,286.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report